MeiraGTx Q2 revenue jumps on Reogen license revenue - MGTX News | Rallies

MeiraGTx Q2 revenue jumps on Reogen license revenue

MGTX•2026-08-13

Outlook

Company expects global regulatory filings for bota-vec in 2026 and potential launch in 2027
MeiraGTx plans potential BLA filing for AAV2-hAQP1 in mid-2027, targeting U.S. launch in 2028
Company expects to initiate Phase 3 study of AAV-GAD for Parkinson’s disease in coming months

Analyst coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for MeiraGTx Holdings PLC is $26.00, about 100.6% above its August 12 closing price of $12.96

Key financial details

Metric	Actual
Q2 Revenue	$321.43 mln

Related News

CareCredit survey shows Americans overlook chiropractic care in long-term wellness routines, Synchrony says

SYF•2026-08-13

MapLight Therapeutics prices USD 150 million PIPE at USD 11.38 a share

MPLT•2026-08-13

Boa Acquisition Corp II units to split into Nasdaq-listed shares, rights on Aug. 14